New Eczema Survey Highlights Access Issues; NEA Takes on Step Therapy and Treatment Delays

Nearly 40% of eczema patients and caregivers reported at least one insurance coverage issue in the past year, and 15% never started a prescribed medication due to insurance barriers, according to a new survey from the National Eczema Association (NEA) presented on Capitol Hill.

The hour-long briefing, Tackling Step Therapy, Treatment Delays, and Research Funding, featured presentations by Kristin Belleson, MBA, CAE, NEA President & CEO, Wendy Smith Begolka, MBS, NEA Chief Program and Mission Officer, and Jiwon Park, an eczema patient and NEA Advocacy Ambassador from San Antonio, Texas.

Fully 12% had to discontinue a prescription due to coverage issues, the survey showed. More than 35% of those who experienced coverage issues faced step therapy, with nearly one in four asked to retry a medication that had been previously tried, and 56% faced prior authorization.

In addition, 52% of those who changed insurance in the past year faced a coverage issue from their new insurer. Eighteen percent of those with coverage issues also reported confusion or miscommunication about the coverage status or copay amount.

NEA’s Policy Recommendations

NEA leaders advocated for legislators to support the following policy recommendations during the briefing:

  • Cosponsor and support the Safe Step Act (H.R. 5509/S. 2903), which would require insurers to implement a clear and transparent process for a patient or healthcare provider to request an exception to step therapy.
  • Cosponsor and support the HELP Copays Act (H.R. 6423/S. 864), which closes a loophole that allows many employer health plans to deem certain covered drugs as “nonessential,” which means that the insurer will not count any cost-sharing toward the patient’s deductible and out-of-pocket maximum.
  • Continue to include “eczema” in the Department of Defense’s Peer-Reviewed Medical Research Program (PRMRP) in Fiscal Year 2027.

“The science has moved forward, but coverage policy has not kept pace,” says Belleson in a news release. “No patient should be required to fail first before receiving the treatment their physician recommends. Insurance barriers are delaying care for millions of Americans living with eczema. Congress has the opportunity to reduce unnecessary step therapy requirements and ensure patients can access the care their physicians prescribe.”

PHOTO CAPTION: NEA’s Chief Program and Mission Officer Wendy Smith Begolka presents new research on eczema prescription treatment access and affordability at the recent Congressional Briefing in Washington, DC.